Centre Hospitalier Jean Rougier — Clinical Trial Site

21 Registered trials

9 Currently recruiting

Organisation

Centre Hospitalier Jean Rougier

Location

Cahors, France

Identifier

ORG-100042017

Address

52 Place Antonin Bergon, Bp 50269, 46000, France

Departments

Anesthesie réanimation
Centre Hospitalier Général Jean Rougier - Service de Rhumatologie
Department of Rheumatology
Hematology
Maladies Infectieuses et Tropicales
Médical Oncology
Oncologie
Oncologie médicale
oncologist
Oncology
oncology rhumatology
Rheumatology
Rheumatology Department
Service de rhumatologie
Service de Rhumatologie Rééducation fonctionnelle
Service des Maladies Respiratoires et Allergiques
SMIT

Clinical trials at this site (21)

Search interface

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis Recruiting

2024-511871-13-00 Postmenopausal osteoporosis 6 2025-10-02
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 colon carcinoma 5 2024-06-07
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterre… Recruiting

2024-514952-34-00 Catheter related bloodstream infections due to Staphylo 5 2023-06-23
Efficacy of a sequential treatment strategy in Rheumatoid Arthritis. Recruiting

2022-500234-29-00 Rheumatoid Arthritis 5 2022-11-28
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting

2024-516704-41-00 Rheumatoid Arthritis 11 2016-03-30
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU “START-or-N… Ended

2024-515845-40-00 Acute kidney injury 5 2022-11-22
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended

2024-513005-31-00 Patients with untreated metastatic Estrogen Receptor po 5 2020-06-11
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended

2022-502799-22-00 Knee osteoarthritis pain 4 2023-11-29
A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended

2024-514934-19-00 Post-surgical neuropathic pain 5 2021-11-08
Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo… Ended

2024-514586-20-01 Non small cell lung cancer 5 2018-05-02
Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease's lymphadenitis Ended

2024-512037-32-00 Bartonellosis 5 2017-05-31